Seven Inhalers That Use CFCs Being Phased Out
On April 13, 2010, the Food and Drug Administration (FDA) announced that seven metered dose inhalers that contain chlorofluorocarbons (CFCs) are being phased out in the United States.
These inhalers use CFCs as propellants to spray the medicine out of the inhaler so patients can breathe the medicine into their lungs.
The seven CFC inhalers are used for the treatment of asthma or chronic obstructive pulmonary disease (COPD) or both. Both diseases cause a decrease in air flow to the lungs.
More information about the phase-out—and about inhalers that do not contain CFCs—follows.
Which CFC inhalers are being phased out, and when?
Dates for the phase-out of each CFC inhaler have been set. After those dates, these CFC inhalers cannot be made, dispensed, or sold in the United States.
The seven CFC inhalers are listed here by their brand names, along with their manufacturers and the last date they can be sold in the United States. The generic names for the medicines appear in parentheses.
- Tilade Inhaler (nedocromil), made by King Pharmaceuticals, last date for sale: June 14, 2010
- Alupent Inhalation Aerosol (metaproterenol), made by Boehringer Ingelheim Pharmaceuticals, last date for sale: June 14, 2010
- Azmacort Inhalation Aerosol (triamcinolone), made by Abbott Laboratories, last date for sale: Dec. 31, 2010
- Intal Inhaler (cromolyn), made by King Pharmaceuticals, last date for sale: Dec. 31, 2010
- Aerobid Inhaler System (flunisolide), made by Forest Laboratories, last date for sale: June 30, 2011
- Combivent Inhalation Aerosol (albuterol and ipratropium in combination), made by Boehringer Ingelheim Pharmaceuticals, last date for sale: Dec. 31, 2013
- Maxair Autohaler (pirbuterol), made by Graceway Pharmaceuticals, last date for sale: Dec. 31, 2013
Four of the seven CFC inhalers are no longer being made. Three CFC inhalers currently in use—Aerobid, Combivent, and Maxair—will be phased out over the next one to three years. These later phase-out dates give patients time to talk with their health care professionals and switch to another medicine.
FDA will continue to reach out to companies, health care professionals, and patients to ensure a smooth transition.
What should I do if I use one of the seven CFC inhalers being phased out?